Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gianantonio Rosti

Showing results (61-70 of 153) with videos related to

Pageof 16
Sort By:
Critical Reviews in Oncology/Hematology|January 11, 2014
Current management of CML patients: Summary of the Italian Consensus Meeting held in Rome, April 11-12, 2013Massimo Breccia, Giuliana Alimena, Michele Baccarani, et al.
BMC Cancer|August 4, 2016
In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutantsSimona Soverini, Caterina De Benedittis, Fausto Castagnetti, et al.
Blood|December 17, 2013
Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinibTimothy P Hughes, Giuseppe Saglio, Hagop M Kantarjian, et al.
Haematologica|March 28, 2008
Front-line treatment of Philadelphia positive chronic myeloid leukemia with imatinib and interferon-alpha: 5-year outcomeFrancesca Palandri, Ilaria Iacobucci, Fausto Castagnetti, et al.
Leukemia|January 19, 2026
Treatment-free remission after two nilotinib consolidation durations in chronic myeloid leukemia treated with imatinib: Phase 3 ENESTPath resultsDelphine Rea, Slawomira Kyrcz-Krzemien, Paolo Sportoletti, et al.
The Lancet. Oncology|August 23, 2011
Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trialHagop M Kantarjian, Andreas Hochhaus, Giuseppe Saglio, et al.
International Journal of Molecular Sciences|January 11, 2024
<i>ETV6::ABL1</i>-Positive Myeloid Neoplasm: A Case of a Durable Response to Imatinib Mesylate without Additional or Previous TreatmentMaria Teresa Bochicchio, Giovanni Marconi, Carmen Baldazzi, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|November 12, 2019
Validation of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 Summary Score in Patients With Hematologic MalignanciesFabio Efficace, Francesco Cottone, Kathrin Sommer, et al.
Haematologica|January 19, 2007
Impact of age on the outcome of patients with chronic myeloid leukemia in late chronic phase: results of a phase II study of the GIMEMA CML Working PartyGianantonio Rosti, Ilaria Iacobucci, Simona Bassi, et al.
Blood|April 18, 2012
Definitions, methodological and statistical issues for phase 3 clinical trials in chronic myeloid leukemia: a proposal by the European LeukemiaNetJoëlle Guilhot, Michele Baccarani, Richard E Clark, et al.
Pageof 16

Showing results (61-70 of 153) with videos related to

Sort By:
Pageof 16
Critical Reviews in Oncology/Hematology|January 11, 2014
Current management of CML patients: Summary of the Italian Consensus Meeting held in Rome, April 11-12, 2013Massimo Breccia, Giuliana Alimena, Michele Baccarani, et al.
BMC Cancer|August 4, 2016
In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutantsSimona Soverini, Caterina De Benedittis, Fausto Castagnetti, et al.
Blood|December 17, 2013
Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinibTimothy P Hughes, Giuseppe Saglio, Hagop M Kantarjian, et al.
Haematologica|March 28, 2008
Front-line treatment of Philadelphia positive chronic myeloid leukemia with imatinib and interferon-alpha: 5-year outcomeFrancesca Palandri, Ilaria Iacobucci, Fausto Castagnetti, et al.
Leukemia|January 19, 2026
Treatment-free remission after two nilotinib consolidation durations in chronic myeloid leukemia treated with imatinib: Phase 3 ENESTPath resultsDelphine Rea, Slawomira Kyrcz-Krzemien, Paolo Sportoletti, et al.
The Lancet. Oncology|August 23, 2011
Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trialHagop M Kantarjian, Andreas Hochhaus, Giuseppe Saglio, et al.
International Journal of Molecular Sciences|January 11, 2024
<i>ETV6::ABL1</i>-Positive Myeloid Neoplasm: A Case of a Durable Response to Imatinib Mesylate without Additional or Previous TreatmentMaria Teresa Bochicchio, Giovanni Marconi, Carmen Baldazzi, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|November 12, 2019
Validation of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 Summary Score in Patients With Hematologic MalignanciesFabio Efficace, Francesco Cottone, Kathrin Sommer, et al.
Haematologica|January 19, 2007
Impact of age on the outcome of patients with chronic myeloid leukemia in late chronic phase: results of a phase II study of the GIMEMA CML Working PartyGianantonio Rosti, Ilaria Iacobucci, Simona Bassi, et al.
Blood|April 18, 2012
Definitions, methodological and statistical issues for phase 3 clinical trials in chronic myeloid leukemia: a proposal by the European LeukemiaNetJoëlle Guilhot, Michele Baccarani, Richard E Clark, et al.
Pageof 16